Global Cancer Monoclonal Antibodies Market 2017-2021

December 27, 2016
This market research report identifies F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, and Takeda Pharmaceuticals as the key vendors in the global cancer mAbs market. This report also presents a detailed segmentation of the market by types (naked and conjugated mAbs), MOA (immune system suppressors, kill or inhibit malignant cells, angiogenesis inhibitor, deliver radiation to cancer cells, and deliver chemotherapy to cancer cells), and geography (the Americas, APAC, and EMEA).

Overview of the global cancer monoclonal antibodies (mAbs) market

Technavio’s market research analyst predicts the global cancer monoclonal antibodies (mAbs) market to grow at a CAGR of around 11% by 2021. At present, the market is witnessing the emergence of targeted and combination therapies for the treatment of cancers and inflammatory diseases. These therapies exploit the surface properties of the infected cells and cause fewer adverse side effects than the conventional non-targeted therapies. As targeting multiple pathways minimizes the threat of developing treatment-resistant disorders, combination therapies are highly preferable in treating cancers. Also, several vendors in the market are collaborating and entering strategic alliances to develop and market the novel drugs. For instance, Seattle Genetics collaborated with Bristol-Myers Squibb to launch a combination of OPDIVO and ADCETRIS to treat hematologic malignancies.

In terms of geography, the cancer mAbs market in the Americas is growing at a steady rate due to the higher acceptance of existing cancer mAbs and the introduction of new ones. Also, the region is likely to witness accelerated approvals for specific formulations and pipeline molecules, encouraging more vendors to conduct research activities in the market. Recently, the US FDA granted accelerated approval to daratumumab injection (DARZALEX) for the treatment of multiple myelomas.

Competitive landscape and key vendors

The global cancer mAbs market is marked by the presence of established vendors such as F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, and Takeda Pharmaceuticals. F. Hoffmann-La Roche is the leading vendor in the market and holds the maximum market share by its broad range of mAbs, including Avastin, PERJETA, MabThera/Rituxan, KADCYLA, and Herceptin. The possibility of new vendors entering this market is quite high owing to the massive growth potential this market offers, however, the presence of extremely stringent guidelines for cancer mAbs manufacturing will also pose restrictions for them.

Leading vendors in the market are -

  • F. Hoffmann-La Roche
  • Amgen
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals

Other prominent vendors in the cancer mAbs market include AbbVie, ADC Therapeutics, Agensys, Argos Therapeutics, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, BioGenomics, Boehringer Ingelheim, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, Merck, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed Pharmaceuticals, Pfizer, Sanofi, Seattle Genetics, TG Therapeutics, and Xbiotech.

Segmentation by types and analysis of the cancer mAbs market

  • Naked mAbs
  • Conjugated mAbs

Naked mAbs are the most commonly used mAbs and are also termed as targeted therapies. They do not have a radioactive material or drug attached to them. The naked mAbs attach to the cancer cells to act as a marker for the body’s immune system to destroy them. Their capability to attach to antigens of cancerous cells or other cells that help in the growth of cancer cells is the major factor in the growth of this segment. Herceptin and Avastin are the two most popular US FDA-approved naked mAbs.

Segmentation by MOA and analysis of the cancer mAbs market

  • Immune system suppressors
  • Kill or inhibit malignant cells
  • Angiogenesis inhibitors
  • Deliver radiation to cancer cells
  • Deliver chemotherapy to cancer cells

The immune system does not identify all cancerous cells as invaders. Cancer mAbs attach themselves to specific parts of a cancerous cell, marking the cancer cell and making it convenient for the immune system to locate such abnormal cancer cells. For instance, Rituximab attaches itself to the protein CD20, which is found on healthy as well as malignant B cells and one type of WBC.

 Key questions answered in the report include

  • What will the market size and the growth rate be in 2021?
  • What are the key factors driving the global cancer mAbs market?
  • What are the key market trends impacting the growth of the global cancer mAbs market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global cancer mAbs market?
  • What are the market opportunities and threats faced by the vendors in the global cancer mAbs market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of the global cancer mAbs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports: